GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Akums Drugs and Pharmaceuticals Ltd (BOM:544222) » Definitions » Net Income

Akums Drugs and Pharmaceuticals (BOM:544222) Net Income : ₹2,826 Mil (TTM As of Sep. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Akums Drugs and Pharmaceuticals Net Income?

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax. Akums Drugs and Pharmaceuticals's Net Income for the six months ended in Sep. 2024 was ₹1,254 Mil. Its Net Income for the trailing twelve months (TTM) ended in Sep. 2024 was ₹2,826 Mil.

Net Income is linked to the most popular Earnings per Share (Diluted) number. Akums Drugs and Pharmaceuticals's Earnings per Share (Diluted) for the six months ended in Sep. 2024 was ₹8.58.


Akums Drugs and Pharmaceuticals Net Income Historical Data

The historical data trend for Akums Drugs and Pharmaceuticals's Net Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Akums Drugs and Pharmaceuticals Net Income Chart

Akums Drugs and Pharmaceuticals Annual Data
Trend Mar21 Mar22 Mar23 Mar24
Net Income
1,227.05 -2,508.74 978.17 7.90

Akums Drugs and Pharmaceuticals Semi-Annual Data
Mar21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24
Net Income Get a 7-Day Free Trial 686.08 292.09 -1,564.17 1,572.07 1,253.77

Akums Drugs and Pharmaceuticals Net Income Calculation

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax.

Net Income
= Revenue - Cost of Goods Sold - Selling, General, & Admin. Expense - Research & Development - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= EBITDA - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Operating Income - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Pre-Tax Income - Tax Expense + Others

Akums Drugs and Pharmaceuticals's Net Income for the fiscal year that ended in Mar. 2024 is calculated as

Net Income(A: Mar. 2024 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=-452.78+460.68+0+-3.3750779948605E-14
=8

Akums Drugs and Pharmaceuticals's Net Income for the quarter that ended in Sep. 2024 is calculated as

Net Income(Q: Sep. 2024 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=1790.64+-512.05+0+-24.82
=1,254

Net Income for the trailing twelve months (TTM) ended in Sep. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was ₹2,826 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Akums Drugs and Pharmaceuticals  (BOM:544222) Net Income Explanation

Net Income is the most widely cited number in reporting a company's profitability. It is linked to the most popular earnings-per-share (EPS) number through:

Akums Drugs and Pharmaceuticals's Earnings per Share (Diluted) (EPS) for the quarter that ended in Sep. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

EPS is most useful for companies that have:

A predictable business
Consistent accounting methods
And few restructurings

The dividend paid to preferred stocks needs to be subtracted from the total net income in the calculation of EPS because common stock holders are not entitled to that part of the net income.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred Net Income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Akums Drugs and Pharmaceuticals Net Income Related Terms

Thank you for viewing the detailed overview of Akums Drugs and Pharmaceuticals's Net Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Akums Drugs and Pharmaceuticals Business Description

Traded in Other Exchanges
Address
Akums House, Plot No. 131 to 133, Block C, Mangolpuri Industrial Area Phase1, Adjoining CBSE Office, Delhi, IND, 110083
Akums Drugs and Pharmaceuticals Ltd a pharmaceutical contract development and manufacturing organization (CDMO) offering a comprehensive range of pharmaceutical products and services in India and overseas. Its services include formulation research and development (R&D), preparation and filing of regulatory dossiers in the Indian and Outside markets, and other testing services. It is also engaged in the manufacturing and sale of branded pharmaceutical formulations and active pharmaceutical ingredients (APIs). The operates in three segments: a) Contract Development and Manufacturing Operations (CDMO), b) Active Pharmaceutical Ingredient (API), and c) Branded and Generic formulations. Key revenue is generated from Contract Development and Manufacturing Operations (CDMO).

Akums Drugs and Pharmaceuticals Headlines

No Headlines